This report was first published by Endpoints News. To see the original version, click here
Biotech takeover specialist Kevin Tang is consolidating control at Aurinia Pharmaceuticals, and has replaced the CEO and C-suite at the company, according to a securities filing Monday.
Tang, who serves as chairman of the board, named himself CEO. Ryan Cole and Michael Hearne, executives at Tang’s firm Tang Capital Management, have been named COO and CFO, respectively. Thomas Wei, a managing director at Tang Capital, has also been named chief scientific officer, according to the SEC filing and a related press release.
您已阅读29%（612字），剩余71%（1491字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。